For patients suffering from breast cancer, the highest risk of the development of BMs is correlated with human epidermal growth factor receptor 2 positive (HER-2+) breast cancer, with up to half of patients developing BMs during the course of the disease [10,11]. Here, ERBB2 is linked to breast carcinoma.